Breaking News, Collaborations & Alliances

SanegeneBio, Lilly Enter RNAi Licensing and Research Pact

Companies will collaborate on RNAi research for metabolic disease targets.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

SanegeneBio

SanegeneBio, a clinical-stage biotechnology company developing RNAi therapeutics, entered a global research and licensing collaboration with Eli Lilly and Co. The companies will collaborate to advance RNAi candidates for metabolic diseases, based on SanegeneBio’s tissue selective delivery technology, LEAD (Ligand and Enhancer Assisted Delivery). SanegeneBio will be responsible for discovery and identification of the optimized LEAD-based RNAi molecule for each program and Lilly will be respons...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters